Introduction

Type 1 diabetes (T1DM) is known to be associated with an increased risk of hip and nonvertebral fractures.\(^\text{1-6}\) Meta-analyses have identified an up to sevenfold increase in hip fractures in patients with T1DM aged between 20 and 60 years.\(^\text{1,4,7}\) In line with this, hip fractures tend to occur 10 to 15 years earlier in patients with T1DM compared with the nondiabetic population.\(^\text{8,9}\) Regarding vertebral fractures there is less evidence available but some studies point to an increased risk of vertebral fractures in patients with T1DM.\(^\text{10-12}\)

The fracture risk in T1DM is accompanied by a reduction in areal BMD (aBMD), particularly at the hip,\(^\text{7,13}\) which is apparent in both male and female patients.\(^\text{14}\) However, the modest reduction in aBMD does not explain the extent of fracture risk. Vestergaard\(^\text{15}\) showed that, based on aBMD, the estimated fracture risk in T1DM is only 1.4-fold higher than in controls. In addition to a reduced aBMD, alterations in bone quality characterized...
by variations in bone remodeling rates as well as changes in bone microarchitecture may represent an important determinant of diabetes-related bone fragility. High-resolution quantitative computer tomography at peripheral sites (HRpQCT) allows to quantitatively assess volumetric bone mineral density (vBMD), bone geometry, and microarchitecture in a compartmental fashion with separate analyses of trabecular and cortical bone compartments. HRpQCT data on bone microarchitecture have been mainly obtained for type 2 diabetes (T2DM); there are only a few data on patients with T1DM. So far, the use of HRpQCT in T1DM revealed mainly differences in the trabecular compartment and trends of higher cortical porosity as compared to nondiabetic controls.

Nowadays life expectancy in patients with T1DM is gradually increasing and more patients will survive long enough to develop fractures. Long exposure to the disease is considered to be an independent risk factor for fractures.

There has been some debate as to whether the presence of microvascular complications in T1DM might impact bone microarchitecture and influence fracture risk. In support of this notion, Shanbhogue and colleagues found an altered bone microarchitecture in cortical and trabecular compartments in patients with T1DM and microvascular disease only. A recent study showed a higher cortical porosity in type I diabetics with diabetic neuropathy compared to patients without neuropathy. However, most studies investigating bone quality in T1DM were performed in patients with relatively short disease duration. Maddaloni and colleagues examined bone health in patients with long-standing T1DM (mean diabetes duration, 52 years) and high rates of microvascular complications, but they did not investigate bone microarchitecture.

Within the present study we aimed to examine the effects of long-standing T1DM (disease duration ≥25 years) on densitometric, microstructural, biochemical and estimated biomechanical bone properties; and to assess whether microangiopathy, a long-term diabetic complication, and specifically diabetic neuropathy, has an independent effect on bone microstructure.

Patients and Methods

Study population

This is a single-center, cross-sectional, case-controlled study. Patients with long-standing T1DM and nondiabetic controls were recruited from the Endocrine Clinic at University Hospital Basel, Switzerland, as well as via press advertisement. The study size of at least 57 subjects per group to reach a given power of 90% was calculated for the comparison of total vBMD according to data from Shanbhogue and colleagues. Subjects were eligible for inclusion if they had type 1 diabetes with a disease duration of at least 25 years with or without microvascular disease. We excluded patients with coexisting metabolic bone disease, a history of osteoporosis, or medical conditions affecting bone health (e.g., hepatic [serum aspartate aminotransferase (AST) more than three times the upper limit of normal] or renal insufficiency [chronic kidney disease stage IV and V], metastatic bone disease, inflammatory bowel disease, thyrotoxicosis, celiac disease, hypogonadism, hyperparathyroidism).

Data on comorbidities, microvascular and macrovascular disease, medication use, historical glycated hemoglobin (HbA1c) levels (2, 5, 7, and 10 years before enrollment), menopausal status, smoking status, alcohol intake, calcium and vitamin D intake, fracture history, family history regarding hip fractures, and falls were obtained during the study visit and from past medical records. Height and weight were measured on site. We assessed lower extremity strength, balance, and gait by performing timed up and go test (time in seconds to rise from an armchair, walk 3 m, turn around 180 degrees, walk back to the chair, and sit down again) and chair-rising test (minimum time in seconds to complete five cycles of rising from a standard chair until standing fully erect and sitting down again with the arms folded across the chest). Fracture Risk Assessment Tool (FRAX) score was calculated using the online fracture risk assessment tool for Switzerland provided by the Centre for Metabolic Bone Diseases at Sheffield University, UK.

Assessment of microvascular complications

The presence of diabetic neuropathy (distal symmetric polyneuropathy) was defined by vibration perception testing using a 128-Hz Riedel Seifler tuning fork at the first metatarsophalangeal joint (grade ≤4/8 in patients >60 years and <6/8 in patients ≤60 years indicating clinical neuropathy according to manufacturer guideline). Data on diabetic retinopathy and/or diabetic nephropathy (presence of urinary albumin creatinine ratio >30 mg/g in a random voided urine sample when ≥2/3 tests were positive) were obtained from past medical records and by interview.

Biochemical assessment

Fasting blood samples were drawn between 8:00 a.m. and 11:00 a.m. After analysis for HbA1c (Alere Afinion; Abbott, Chicago, IL, USA) and fasting glucose, serum samples were stored at −20°C until analysis (analysis within 12 months). Samples were analyzed for calcium, phosphate, 25OH vitamin D, creatinine, urinary calcium, and urinary creatinine by standard method on an autoanalyzer (Cobas Integra 400plus; Roche Diagnostics, Basel, Switzerland). Procollagen type 1 N propeptide (PINP), beta-CrossLaps (CTX), intact parathyroid hormone (iPTH), and 25-Hydroxyvitamin D (25OHHD) were assessed in serum by electrochemiluminescence immunoassays (ECLIA) (Cobas® e411 autoanalyzer; Roche Diagnostics, Rotkreuz, Switzerland). The intraassay and interassay variation was 2.0% to 8.4% for CTX, 1.2% to 3.3% for PINP, 2.2% to 10.7% for 25OHHD, and 1.2% to 2.0% for iPTH, respectively. Serum bone-specific alkaline phosphatase (BAP) was measured by ELISA (MicroVueBAP; Quidel, San Diego, CA, USA) with an intrassay variation of <5.8% and an interassay variation of 7.6%.

aBMD, trabecular bone score, and vertebral fracture assessment

We assessed aBMD at the lumbar spine, hip, and distal radius by dual-energy X-ray absorptiometry (DXA) using a Hologic Discovery densitometer (Horizon A, S/N 200174; Hologic, Bedford, MA; USA). Short-term precision of the densitometer was determined by performing duplicate scans in 20 patients. The following coefficients of variation were calculated: 1.1% (spine), 1.4% (femoral neck), 1.9% (trochanteric region), and 1.1% (total hip). Device quality assurance assessments and regular machine calibrations were performed and monitored according to the manufacturer’s recommendations. Every DXA scan was assessed by the investigator for additional quality control; vertebrae containing foreign material or showing degenerative changes were excluded from aBMD calculation.
TBS iNsight Imaging Software (version 1.8; Med-Imaps, Pessac, France) was used to compute trabecular bone score (TBS) from spine DXA scans.

To screen for prevalent vertebral fractures, we performed vertebral fracture assessment (VFA) on lateral spine scans that were generated alongside DXA scans.

vBMD, bone microarchitecture, and bone strength

Scanning

Subjects were evaluated at the department of osteoporosis, University Hospital of Bern (Inselspital) using an HRpQCT scanner (XtremeCT II; Scanco Medical, Brüttisellen, Switzerland) with standard settings for in vivo measurements (60 kVp, 900 μA, 100 ms integration time) and at an isotropic voxel size of 60.7 μm. A calibration phantom was measured for daily and weekly quality control according to the manufacturer’s protocol. We fixed the nondominant forearm and equilateral leg of each subject in a carbon fiber cast provided by the scanner manufacturer. In case of a previous distal radius or distal tibia fracture the nonfractured side was used: In eight patients with T1DM and 11 controls the nonfractured dominant side was evaluated. Following positioning, the reference line was set on a standard scout view image according to Bonaretti and colleagues. Each measurement was evaluated for bone stiffness and ultimate load using a standardized and validated nonlinear homogenized finite element pipeline published by Hosseini and colleagues and Arias-Moreno and colleagues available on the HRpQCT scanner software (IPL V5.16/FE-v02.02; Scanco Medical AG). A brief overview follows. Brick elements with eight-node and 1.7-mm edge length were created from the downscaled

Estimation of bone strength and stiffness by homogenized finite element analysis

Each measurement was evaluated for bone stiffness and ultimate load using a standardized and validated nonlinear homogenized finite element pipeline published by Hosseini and colleagues and Arias-Moreno and colleagues available on the HRpQCT scanner software (IPL V5.16/FE-v02.02; Scanco Medical AG). A brief overview follows. Brick elements with eight-node and 1.7-mm edge length were created from the downscaled

Table 1. Abbreviations of HR-pQCT Derived Basic Bone Density and Structural Parameters

| Abbreviation | Parameter | Unit of measure |
|--------------|-----------|-----------------|
| Total vBMD   | Total volumetric bone mineral density | mg/cm\(^3\) |
| Tb vBMD      | Trabecular volumetric bone mineral density | mg/cm\(^3\) |
| Ct vBMD      | Cortical volumetric bone mineral density | mg/cm\(^3\) |
| Tb BV/TV     | Trabecular bone volume fraction | % |
| Tb N         | Trabecular number | 1/mm |
| Tb Th        | Trabecular thickness | mm |
| Tb Sp        | Trabecular separation | mm |
| Ct Th        | Cortical thickness | mm |
| Ct Po        | Cortical porosity | % |
| Ct Pr        | Cortical perimeter | mm |
| Ct Po Dm     | Cortical pore diameter | mm |

Abbreviations according to Bonaretti and colleagues.

Fig. 1. Reference line position on scout view images and qualitative visualization of multiple sections. (A) Distal radius: reference line position at the dense articular surface, formed with the scaphoid and lunate fossae of the radiocarpal joint. Scan region: adjacent double section (2 × 168 = 336 slices) without offset. (B) Distal tibia: reference line position at the proximal margin of the dense structure formed by the tibial plafond. Scan region: adjacent proximal triple section (3 × 168 = 504 slices) without offset. (A,B) from; (C) 3D image of the segmented radial double section; (D) 3D image of the segmented tibial triple section.
Table 2. General Characteristics of the Study Population

| Characteristic                      | T1DM (n = 59) | Controls (n = 77) | p   |
|-------------------------------------|---------------|------------------|-----|
| Gender female/male, n               | 24/35         | 47/30            | 0.04|
| Age (years), mean ± SD              | 59.9 ± 9.9    | 60.9 ± 7.5       | 0.50|
| BMI (kg/m²), mean ± SD              | 25.5 ± 3.7    | 25.3 ± 4.0       | 0.53|
| Postmenopausal status, n            | 22            | 46               |     |
| Postmenopausal hormone replacement, n| 2             | 10               | 0.10|
| Smoking (current/past), n           | 9/22          | 10/25            | 0.90|
| Alcohol consumption (U/d), median (IQR) | 0.5 (0.0–1.0) | 0.1 (0.0–0.5)   | 0.01|
| Daily calcium intake (mg), mean ± SD| 740 ± 349     | 799 ± 304        | 0.30|
| Low traumatic fractures, n          | 0             | 0                | 1.00|
| Past traumatic fractures, n         | 20            | 22               | 0.80|
| Fractures assessed by VFA (n = 115), n | 0             | 0                | 1.00|
| Falls in the last 12 months, n      | 0 (0–1)       | 0 (0–0.3)        | 0.44|
| Timed up and go test (seconds), median (IQR) | 6.0 (6.0–8.0) | 6.0 (6.0–7.0)   | 0.90|
| Chair rise test (seconds), median (IQR) | 12.5 (11.0–14.75) | 11.0 (10.0–13.0) | <0.0|

Data are expressed as mean ± SD, median (interquartile range), or numbers (n). Significant values are shown in bold. Values of p were calculated by chi-square or Fisher’s exact test in case of dichotomous variables and by Mann-Whitney test in case of continuous variables.

BMI = body mass index; IQR = interquartile range; VFA = vertebral fracture assessment.

Table 3. Diabetes-Related Parameters

| Parameter                                      | T1DM (n = 59) |
|-----------------------------------------------|---------------|
| Diabetes duration (years), mean ± SD          | 37.7 ± 9.0    |
| Glycemic control                              |               |
| HbA1c (%), median (IQR)                       | 6.8 (5.4–7.4) |
| HbA1c 2 years ago (%), n (n = 46), median (IQR) | 7.1 (6.8–7.8) |
| HbA1c 5 years ago (%), n (n = 32), median (IQR) | 7.1 (6.8–7.4) |
| HbA1c 7 years ago (%), n (n = 17), median (IQR) | 6.9 (6.7–7.2) |
| HbA1c 10 years ago (%), n (n = 18), median (IQR) | 7.0 (6.4–7.5) |
| Fasting glucose (mmol/L), median (IQR)        | 8.6 (7.2–11.2) |
| Hx of hypoglycemia grade II/III, n/N (%)      | 31/59 (52.5)  |
| Hypoglycemia grade II/III, past 12 months, n/N (%) | 6/59 (10.2)  |
| Hypoglycemia grade II/III, past 3 months, n/N (%) | 5/59 (8.5)  |
| Insulin treatment                              |               |
| Mean daily insulin dose (IU), mean ± SD       | 44.4 ± 20.6   |
| Functional insulin therapy, n/N (%)            | 35/59 (59.3)  |
| Conventional basis/bolus therapy, n/N (%)     | 24/59 (40.7)  |
| Microvascular and macrovascular complications, n/N (%) |               |
| Retinopathy                                    | 26/59 (44.1)  |
| Nephropathy, defined as microalbuminuria       | 10/59 (16.9)  |
| Diabetic peripheral neuropathy                 | 22/59 (37.2)  |
| Diabetic foot syndrome                         | 2/59 (3.5)    |
| Presence of any microangiopathy                | 38/59 (64.4)  |
| Cardiac disease                                | 10/59 (16.9)  |
| Peripheral arterial disease                    | 4/59 (6.8)    |
| More severe disease*a                         | 22/59 (37.3)  |

Statistical analysis

Baseline characteristics were described as percentage of participants, or mean ± standard deviation (SD) if normally distributed, and median and interquartile range (IQR) if not. The analysis was performed separately for T1DM and controls. To compare the baseline characteristics, a Mann-Whitney U test was used to test for differences between continuous variables, and a chi square test or a Fisher’s exact test for categorical variables.

Multivariable logistic regression analyses were implemented for further analyses of data. Multivariable models were built with each bone score measured by DXA or HRpQCT as dependent
variables, and age, sex, body mass index (BMI), and diagnosis (T1DM versus control) as independent variables. We performed a second multivariable analysis in the T1DM patient group discriminating for presence of polyneuropathy measured by vibration perception test. The multivariable models were built using bone parameters as dependent variables and age, gender, BMI, and presence of diabetic neuropathy as independent variables. Data were analyzed using R software\(^14\) version 4.0.0 (2020-04-24; R Foundation for Statistical Computing, Vienna, Austria).

### Results

#### General characteristics of the study population

We recruited 59 patients with T1DM and 77 nondiabetic controls (CO) for this study. Table 2 shows the characteristics of all participants. A p value of <0.05 was considered significant. There were no significant differences in age and BMI. Gender distribution was unevenly balanced with more women in the control group (24 T1DM versus 47 CO) and more men in the diabetic group (35 T1DM versus 30 CO). More women in the control group were postmenopausal (p = 0.04). Alcohol intake was higher in patients with T1DM (p = 0.01). There were no significant differences in fracture prevalence including occult vertebral fractures, nor differences in the prevalence of smoking or daily calcium intake. Participants with T1DM needed significantly more time for the chair rising test (p < 0.01) than controls, whereas no difference was observed for the timed up and go test.

#### Diabetes-related parameters

T1DM patients had a mean disease duration of 37.7 years (Table 3).

### Glycemic control

Median Hba1c level was 6.8%. Long-term glycemic control was documented by historical HbA1c data: median HbA1c was 7.1% 2 years ago, 7.1% 5 years ago, 6.9% 7 years ago and 7.0% 10 years ago. A total of 31 T1DM patients (52.5%) reported a history of severe hypoglycemia grade II and III.
Microvascular and macrovascular complications

A total of 38 diabetic patients (64.4%) had evidence of any microangiopathy. 26 patients (44.1%) suffered with diabetic retinopathy; 10 patients (16.9%) had diabetic nephropathy defined as evidence of microalbuminuria; 22 patients (37.2%) were diagnosed with diabetic peripheral neuropathy. Patients with and without diabetic neuropathy were comparable in terms of diabetes duration, glycemic control, episodes of severe hypoglycemia, and frequency of falls (Table S1).

More severe disease, defined as at least two diabetic microvascular or macrovascular complications, was found in 22 patients (37.2%).

Biochemical assessment

There were no significant differences in phosphate, iPTH and creatinine levels between T1DM and controls (Table 4). We saw a tendency toward lower 25OH Vitamin D levels in T1DM ($p = 0.05$). Albumin-corrected calcium was significantly higher in patients with T1DM ($p = 0.02$) but absolute differences were minimal.

After adjustment for age, gender, and BMI, serum CTX was significantly decreased in T1DM ($p < 0.01$) whereas there were no significant differences in PINP and BAP between T1DM and controls (Table 5). CTX was not significantly different between patients with and without diabetic neuropathy in a multivariate model.

---

**Table 6. Ultradistal Tibia: Comparison of HRpQCT Data in T1DM and Controls and T1DM DN+ and T1DM DN− Matched by Age, Gender, and BMI**

| Parameter                          | Estimate T1DM versus CO | 95% CI       | $p$   | Estimate T1DM DN+ versus T1DM DN− | 95% CI       | $p$   |
|------------------------------------|-------------------------|--------------|-------|-----------------------------------|--------------|-------|
| **Volumetric density**             |                         |              |       |                                   |              |       |
| Total vBMD (mg/cm³)                | −14.28                  | −30.19, 1.62 | 0.08  | −20.96                            | −46.93, 5.01 | 0.11  |
| Ct vBMD (mg/cm³)                   | −28.66                  | −54.38, −2.93| **0.03**| −49.28                            | −90.04, −8.52| **0.02**|
| Tb vBMD (mg/cm³)                   | −6.76                   | −19.88, 6.37 | 0.31  | −1.23                             | −20.45, 17.98| 0.90  |
| **Microarchitecture**              |                         |              |       |                                   |              |       |
| Tb BV/TV                           | −0.01                   | −0.03, 0.01  | 0.2   | 0.005                             | −0.02, 0.03  | 0.66  |
| Tb N (1/mm)                        | −0.02                   | −0.09, 0.05  | 0.61  | 0.05                             | −0.09, 0.18  | 0.50  |
| Tb Th (mm)                         | −0.003                  | −0.01, 0.004 | 0.43  | −0.004                            | −0.02, 0.01  | 0.45  |
| Tb Sp (mm)                         | 0.005                   | −0.03, 0.04  | 0.74  | −0.04                             | −0.09, 0.01  | 0.14  |
| Ct Th (mm)                         | −0.14                   | −0.24, −0.05 | **<0.01**| −0.11                             | −0.27, 0.05  | 0.15  |
| Ct Po (%)                          | −0.001                  | −0.004, 0.003| 0.65  | 0.001                            | −0.003, 0.004| 0.73  |
| Ct Pm (mm)                         | −2.12                   | −5.13, 0.88  | 0.16  | 4.87                             | −0.96, 10.69 | 0.10  |
| Ct Po Dm (mm)                      | −0.005                  | −0.01, 0.002 | 0.15  | −0.009                           | −0.02, 0.003 | 0.14  |
| **FE analysis**                    |                         |              |       |                                   |              |       |
| Bone stiffness (N/mm)              | −8902.3                 | −14380.5, −3424.2| **<0.01**| −11247.0                         | −19844.9, −2649.1| **0.01**|
| Bone strength (N)                  | −2216.38                | −3822.9, −609.8| **<0.01**| −2927.97                         | −5328.8, −527.1| **0.02**|

Data are shown as estimates with a 95% confidence interval. Significant values are shown in bold. Values of $p$ were calculated by a multivariate linear regression model adjusted for age, gender, and BMI.

T1DM DN+ = T1DM with diabetic neuropathy; T1DM DN− = T1DM without diabetic neuropathy.

---

**Fig. 2.** Cortical vBMD (A) and cortical thickness (B) at the ultradistal tibia in nondiabetic controls and T1DM with and without diabetic neuropathy. Values of $p$ were calculated by a multivariate regression model adjusted for age, sex, and BMI. Ct vBMD = cortical vBMD; Ct.Th = cortical thickness; T1DM DN− = T1DM without diabetic neuropathy; T1DM DN+ = T1DM with diabetic neuropathy.
regression model adjusted for age, gender, and BMI (estimate, [95% confidence interval]: 0.03, [−0.05, 0.11], p = 0.47).

aBMD at the spine, hip, and distal radius

In patients with T1DM (n = 59) we found a significantly lower aBMD at the total hip compared to controls (n = 77) (p < 0.001) as shown in Table 5. aBMD at the lumbar spine (p = 0.04), femoral neck (p = 0.05), and distal radius (p = 0.01) was lower in patients with T1DM after correction for age, gender, and BMI. aBMD at the total hip did not significantly differ in diabetic patients with and without diabetic peripheral neuropathy in a multivariate regression analysis (estimate, [95% confidence interval]: −0.01, [−0.07, 0.04], p = 0.61).

Although there was a trend toward lower TBS in patients with T1DM, findings were not significant. The FRAX scores for hip (p < 0.01) and major osteoporotic fractures (p = 0.02) were significantly higher among the diabetic group. Two patients with T1DM and none from the control group reached the intervention threshold for bone-specific medical treatment based on the 10-year risk of a major osteoporotic fracture in Switzerland as defined by the Swiss Association against Osteoporosis (SVGO).36

HRpQCT data at the ultradistal tibia and radius

We performed HRpQCT in 51 patients with T1DM and 64 controls. All findings were adjusted for age, gender, and BMI.

**Ultradistal tibia**

vBMD, bone microarchitecture, and bone strength in T1DM and controls

We found a significantly reduced cortical thickness (p < 0.01) and reduced cortical vBMD (p = 0.03) in patients with T1DM.
compared to controls (Table 6). Although we observed a trend toward lower total vBMD in T1DM, findings were not significant. Trabecular vBMD and trabecular microarchitecture were not significantly altered in T1DM. Bone strength ($p < 0.01$) and bone stiffness ($p < 0.01$) were significantly reduced in T1DM in comparison to their control counterparts.

vBMD, bone microarchitecture, and bone strength in T1DM with and without neuropathy

We further characterized the diabetes associated cortical bone deficit at the tibia comparing patients with and without diabetic neuropathy (DN) to nondiabetic controls.

Participants with T1DM and DN (T1DM DN+) showed a significantly reduced cortical vBMD ($p < 0.01$) compared to controls. Cortical vBMD was not significantly different between T1DM without DN (T1DM DN−) and controls ($p = 0.41$). T1DM DN+ had a significantly lower cortical vBMD than T1DM DN− (Fig. 2A).

Findings for cortical thickness followed a similar pattern with reduced cortical thickness ($p < 0.01$) in T1DM DN+ as compared to controls. Cortical thickness was not significantly different in T1DM DN− compared to controls, and T1DM DN+ compared to T1DM DN− (Fig. 2B).

We compared cortical vBMD in T1DM with any microangiopathy to T1DM without microangiopathy: Cortical vBMD at the tibia was not significantly lower in patients with any microangiopathy (estimate, [95% confidence interval]: $-32.82$, $[-38.76, -26.87]$, $p = 0.05$). Similarly, patients with more severe disease, defined as a diagnosis of at least two microvascular or macrovascular complications, did not show a significantly decreased cortical vBMD at the tibia (estimate, [95% confidence interval]: $-37.45$, $[-43.82, -31.08]$, $p = 0.07$).

T1DM DN+ had a significantly lower estimated bone strength ($p = 0.02$) and bone stiffness ($p = 0.01$) compared to T1DM DN−. When comparing T1DM DN− with controls there was no significant difference in bone strength or stiffness. T1DM DN+ showed a highly significant reduction in bone stiffness ($p < 0.001$) and bone strength ($p < 0.001$) compared to nondiabetic controls. (Fig. 3A,B).

Ultradistal radius

No significant differences between T1DM and controls were observed for total, cortical, and trabecular volumetric density at the ultradistal radius (Table 7). Except for a significantly lower cortical perimeter ($p < 0.01$) in T1DM, none of the other microarchitectural parameters was significantly different between T1DM and controls. Although estimates of bones stiffness and bone strength were lower in patients with T1DM compared to controls, findings were not significant.

Discussion

This is the first study to assess bone mineral density, bone microarchitecture, biochemical, and estimated biomechanical bone parameters in patients with long-standing, well-controlled T1DM. Compared to nondiabetic controls we observed a reduced aBMD at all measured sites, low CTX, a marker of bone resorption, and a cortical bone deficit at the ultradistal tibia with impaired bone strength and bone stiffness as modeled by hFe analysis. Both the reduced cortical vBMD and lower cortical thickness as well as the significantly altered biomechanical parameters were dependent on the presence of diabetic peripheral neuropathy.

In our cohort of patients with a mean age of 60 years with excellent long-term glycemic control, we found a highly significant aBMD reduction at the total hip as well as a reduced aBMD at the femoral neck, lumbar spine, and distal radius. A recent, large study comparing aBMD in children and adults with T1DM to healthy controls did not reveal aBMD differences across age groups, except for a reduced aBMD in postmenopausal women at the spine, femoral neck, and total hip. However, in line with our findings, most studies in adult T1DM show a reduction in aBMD with a meta-analysis reporting an average decrease of $-22\%$ in spine BMD and of $-37\%$ in hip Z-score. T1DM has been reported to be a state of low bone turnover with reduced bone formation and bone resorption as a potential determinant of altered bone microstructure. We found significantly lower CTX in our cohort of long-standing, nonfracturing T1DM. Bone resorption assessed by CTX might underestimate actual bone resorption as enzymatic collagen cross-linking is impaired in diabetes and CTX assay measures cross-linked telopeptides. Interestingly, we did not see any significant differences in P1NP or BAP between T1DM and controls. In a meta-analysis Hygum and colleagues showed that P1NP was not significantly different between patients with diabetes and controls. The gold standard for estimation of bone turnover in diabetes is bone tissue biopsy: In 1995, Krakauer and colleagues performed bone biopsies in two male patients with long-standing T1DM and found low bone turnover, yet no data is available regarding glycemic control. Armas and colleagues reported no differences in bone turnover between T1DM and controls in a large histomorphometry study in patients with well-controlled T1DM (median HbA1c 6.8%) and a disease duration of 15 years. Whether glycemic control may influence bone turnover in long-standing T1DM remains to be elucidated. Our findings indicate that long-standing, well-controlled diabetes is associated with low bone resorption and unaltered bone formation demonstrated by P1NP and BAP but further research is warranted.

In line with the imbalanced remodeling, we observed microarchitectural changes with a lower cortical vBMD and lower cortical thickness at the ultradistal tibia as measured by HRpQCT. In contrast, no such changes were seen at the ultradistal radius. HRpQCT measurement at the ultradistal radius is more prone to motion artefacts than assessment at the tibia, which may have compromised our data. Yet there is compelling evidence indicating a differing fracture risk at the radius and tibia in T1DM: In a recent meta-analysis Wang and colleagues reported a significant increase in ankle fractures in patients with T1DM (risk ratio [RR] 1.71; 95% CI [1.06, 2.78]; $p = 0.029$), which was more pronounced than in T2DM. Vilaca and colleagues showed that diabetes is associated with an increase in the risk of ankle fractures and a decrease in wrist fractures, but most data were obtained from T2DM.

We speculate that our discrepant findings at the tibia and radius may be related to the fact that the ultradistal tibia is a weight-bearing bone, unlike the radius. Bone adjusts to loading by adaptation of bone mass and microarchitecture. Our diabetic cohort with a mean age of 60 years showed worse chair rise performance potentially reflecting early changes in functional mobility. We did not observe any difference in timed up and go test between T1DM and controls. In contrast to the chair rising test, which apart from assessing balance and coordination mainly reflects muscular power of the lower limbs, timed up and go performance does not focus on a single motor task.
but reflects performance of a variety of daily life activities. We speculate that decreased functional mobility with impairment of lower limb strength might alter mechanical loading and lead to bone loss predominantly affecting weight-bearing bones.

Estimated bone strength and bone stiffness at the tibia were strongly compromised in T1DM. Bone strength is determined by both bone mass and bone quality and is an important determinant of fracture risk. Ultimately, the cortical bone deficit could increase fracture risk at the distal tibia.

It has been reported that long-term hyperglycemia in diabetes favors the accumulation of advanced glycation end-products (AGEs) causing nonenzymatic cross-linking of type I collagen, which seems to impair bone tissue toughness in vitro and in vivo. Despite the reported degradation of tissue-level material properties in two mouse models for diabetes, there was no such evidence in patients with T1DM in a review by Lekkala and colleagues. However, a recent study reported a less than 5% decrease in the median of bone material strength index (BMSi) measured with a reference point indenter (OsteoProbe) in a small cohort of males with T1DM compared to controls. Interestingly, this finding is consistent with the reduction of cortical vBMD observed in our cohort with long-standing T1DM. If the observed decrease in tissue material properties that constitute a necessary input for hFE analysis was confirmed, it would imply an overestimation of bone strength for the T1DM group by a similar amount of about 5%. Although this confirmation will require further research, it would reinforce the substantial reduction in bone strength at the ultradistal tibial observed in T1DM that is mainly attributed to thinning of the cortex.

Cortical bone loss is associated with exposure of intracortical surfaces; incompletely refilled excavated sites increase in number and coalesce leading to increased cortical porosity. T2DM has been widely accepted to be associated with increased cortical porosity. Data for T1DM is less clear; recently Vilaca and colleagues showed a higher cortical porosity in T1DM with diabetic neuropathy. Although we found a decreased cortical vBMD and cortical thickness, we were unable to see any significant differences in cortical porosity between T1DM and controls at the radius or tibia. Results for cortical porosity were highly variable in our population and hence difficult to interpret. Image quality has a major impact on assessment of cortical porosity. Cortical porosity may also have been underestimated by HRpQCT; a study using electron microscopy in women aged 63 years showed that intracortical remodeling by cavitation may leave cortical remnants that were falsely identified as trabecula by HRpQCT.

Our microarchitectural findings with a lower cortical vBMD, cortical thickness, and reduced estimated bone strength and bone stiffness at the tibia were all dependent on the presence of diabetic neuropathy. There was no significant association with other microvascular complications. Hip aBMD and CTX were not significantly altered by the presence of diabetic neuropathy. Diabetic neuropathy is one of the most common complications of diabetes with 54% of T1DM developing diabetic neuropathy over the course of their life. The prevalence increases with diabetes duration, which is a major predictor of diabetic neuropathy. The cross-sectional study design does not allow to draw conclusions about causality, but nevertheless the association of diabetic neuropathy and a cortical bone deficit with reduced estimated bone strength at the tibia only is compelling. Recently, a large prospective study confirmed that bone microstructural changes independently contribute to fracture risk. A recent meta-analysis suggests that patients with diabetic neuropathy have a significantly increased risk of developing osteoporosis and fragility fractures. Different potential mechanisms are being discussed, including a neural dysregulation of vascular supply to the bone (neurovascular hypothesis), gait changes leading to altered mechanical loading with repetitive microtrauma (neurotraumatic hypothesis), or an impaired local neurotransmitter release (neurotrophic hypothesis).

Our finding of an impaired cortical microarchitecture at the ultradistal tibia in T1DM is in contrast to previous data showing mainly differences in the trabecular compartment. Devaraja and colleagues observed an altered trabecular microarchitecture with reduced bone strength at the ultradistal radius and tibia in adolescents with T1DM. In a subanalysis of their study looking at patients with a diabetes duration >2 years, the reduction in load-bearing at the tibia disappeared. Patients with early manifestation of T1DM present with a transiently impaired bone development that normalizes over time.

Shanbhogue and colleagues found alterations in the cortical and trabecular compartment in T1DM with microangiopathy only, another recent case-control study showed changes in the trabecular compartment in T1DM, but no association between microvascular complications and bone microarchitecture. However, most of the studies investigating bone quality in T1DM were performed in patients with an average exposure to hyperglycemia of 16 years—diabetes duration was relatively short in comparison to our study. Diabetic complications and specifically diabetic neuropathy may not have yet manifested its effects on bone at this time, suggesting it may have been too early to see a cortical bone deficit.

It has been proposed that diabetes with microangiopathy is associated with accelerated bone aging. The majority of age-related bone loss at the appendicular skeleton occurs in the cortical compartment; where we observed changes in our diabetic cohort with a mean age of 60 years. Both our microarchitectural findings and densitometric data with a prominent aBMD deficit at the total hip point to a cortical bone deficit. Whether long-standing T1DM with diabetic neuropathy might precipitate age-related bone loss remains to be elucidated.

This present study's findings should be interpreted within the context of its strengths and limitations. Although the comprehensive evaluation of a large cohort of patients with long-standing T1DM with HbA1c data over the past 10 years is a strength, its overall good glycemic control is a limitation. The homogeneity of our diabetic cohort with a mean age of 60 years. Both our microarchitectural findings and densitometric data with a prominent aBMD deficit at the total hip point to a cortical bone deficit. Whether long-standing T1DM with diabetic neuropathy might precipitate age-related bone loss remains to be elucidated.

In conclusion, long-standing, well-controlled T1DM is associated with a decreased aBMD, low bone turnover, and compromised cortical bone at the ultradistal tibia with reduced estimates of bone strength and stiffness. Both the impaired cortical parameters and the altered estimated biomechanical properties at the tibia are dependent on the presence of diabetic neuropathy. Further research is warranted to evaluate whether these structural changes and specifically the presence of diabetic neuropathy can explain the increased fracture risk in T1DM.

Acknowledgements

This work was supported by the Swiss National Science Foundation (grant 320030_169407 to CM). We thank the staff at the
department of osteoporosis, University Hospital of Bern, for their help in coordinating the study. Special thanks go to Claudia Maushart and Matthias Betz for their help with data visualization. Open Access Funding provided by Universitat Basel.

**Author Contributions**

Lilian Sewing: Investigation; methodology; writing – original draft. Laura Potasso: Formal analysis; software. Sandra Baumann: Investigation. Denis Schenk: Data curation; investigation; software. Furkan Gazozcu: Investigation. Kurt Lippuner: Resources; writing – review and editing. Marius Kraenzlin: Resources. Philippe K. Zysset: Data curation; resources; software; writing – review and editing. Christian Meier: Conceptualization; funding acquisition; methodology; resources; supervision; writing – review and editing.

**Conflict of Interest**

All authors state that they have no conflicts of interest with respect to the submitted manuscript.

**Peer Review**

The peer review history for this article is available at [https://publons.com/publon/10.1002/jbmr.4517](https://publons.com/publon/10.1002/jbmr.4517).

**Data Availability Statement**

The data that support the findings of this study are openly available in “figshare” at [https://doi.org/10.6084/m9.figshare.16608316](https://doi.org/10.6084/m9.figshare.16608316).

**References**

1. Janghorbani M, van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495-505.
2. Fan Y, Wei F, Lang Y, Liu Y. Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos Int. 2016;27(1):219-228.
3. Shah VN, Shah CS, Snell-Bergeon JK. Type 1 diabetes and risk of fracture: meta-analysis and review of the literature. Diabetes Care. 2015;38(9):2539-2547.
4. Ha J, Jeong C, Han K-D, et al. Comparison of fracture risk between type 1 and type 2 diabetes: a comprehensive real-world data. Osteoporos Int. 2021;32(12):2543-2553.
5. Shah VN, Harrall KK, Shah CS, et al. Bone mineral density at femoral neck and lumbar spine in adults with type 1 diabetes: a meta-analysis and review of the literature. Osteoporos Int. 2017;28(9):2601-2610.
6. Pan H, Wu N, Yang T, He W. Association between bone mineral density and type 1 diabetes mellitus: a meta-analysis of cross-sectional studies. Diabetes Metab Res Rev. 2014;30(7):531-542.
7. Burghardt AJ, Issever AS, Schwartz AV, et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95(11):5045-5055.
8. Shanbhogue WV, Hansen S, Frost M, et al. Compromised cortical bone compartment in type 2 diabetes mellitus patients with microvascular disease. Eur J Endocrinol. 2016;174(2):115-124.
9. de Waard EAC, de Jong JJA, Koster A, et al. The association between diabetes status, HbA1c, diabetes duration, microvascular disease, and bone quality of the distal radius and tibia as measured with high-resolution peripheral quantitative computed tomography—The Maastricht Study. Osteoporos Int. 2018;29(12):2725-2738.
10. Samelson EJ, Demissie S, Cupples LA, et al. Diabetes and deficits in cortical bone density, microarchitecture, and bone size: Framingham HR-pQCT study. J Bone Miner Res. 2018;33(1):54-62.
11. Starup-Linde J, Lykkeboe S, Gregersen S, et al. Bone structure and predictors of fracture in type 1 and type 2 diabetes. J Clin Endocrinol Metab. 2016;101(3):928-936.
12. Shanbhogue WV, Hansen S, Frost M, et al. Bone geometry, volumetric density, microarchitecture, and estimated bone strength assessed by HR-pQCT in adult patients with type 1 diabetes mellitus. J Bone Miner Res. 2015;30(12):2198-2209.
13. Abdalrahaman N, McComb C, Foster JE, et al. Deficits in trabecular bone microarchitecture in young women with type 1 diabetes mellitus. J Bone Miner Res. 2015;30(8):1386-1393.
14. Leanza G, Maddaloni E, Pitocco D, et al. Risk factors for fragility fractures in type 1 diabetes. Bone. 2019;125:194-199.
15. VavaniKunnel J, Charlier S, Becker C, et al. Association between glycemic control and risk of fracture in diabetic patients: a nested case-control study. J Clin Endocrinol Metab. 2019;104(5):1645-1654.
16. Vilaca T, Paggiosi M, Walsh JS, Selvarajah D, Eastell R. The effects of type 1 diabetes and diabetic peripheral neuropathy on the musculoskeletal system: a case-control study. J Bone Miner Res. 2021;36(6):1048-1059.
17. Keenan HA, Maddaloni E. Bone microarchitecure in type 1 diabetes: it is complicated. Curr Osteoporos Rep. 2016;14(6):351-358.
18. Maddaloni E, D’Eon S, Hastings S, et al. Bone health in subjects with type 1 diabetes for more than 50 years. Acta Diabetol. 2017;54(5):479-488.
19. Bennell K, Dobson F, Hinman R. Measures of physical performance assessments: self-paced walk test (SPWT), stair climb test (SCT), six-minute walk test (6MWT), chair stand test (CST), timed up & go (TUG), sock test, lift and carry test (LCT), and car task. Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S350-S370.
20. Bonaretti S, Majumdar S, Lang TF, Khosla S, Burghardt AJ. The comparability of HP-pQCT bone measurements is improved by scanning anatomically standardized regions. Osteoporos Int. 2017;28(7):2115-2128.
21. Bonaretti S, Vilaypho N, Chan CM, et al. Operator variability in scan positioning is a major component of HP-pQCT precision error and is reduced by standardized training. Osteoporos Int. 2017;28(1):245-257.
22. Pialat JB, Burghardt AJ, Sode M, Link TM, Majumdar S. Visual grading of motion induced image degradation in high resolution peripheral
computed tomography: impact of image quality on measures of bone density and micro-architecture. Bone. 2012;50(1):111-118.

31. Bouxsein ML, Boyd SK, Christiansen BA, Goldberg RE, Jepps KJ, Müller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010;25(7):1468-1486.

32. Hosseini HS, Dünki A, Fabech J, et al. Fast estimation of Colles’ fracture load of the distal section of the radius by homogenized finite element analysis based on HR-pQCT. Bone. 2017;97:65-75.

33. Arias-Moreno AJ, Hosseini HS, Bevers M, Ito K, Zysset P, van Rietbergen B. Validation of distal radius failure load predictions by homogenized- and micro-finite element analyses based on second-generation high-resolution peripheral quantitative CT images. Osteoporos Int. 2019;30(7):1433-1443.

34. Harrigan TP, Mann RW. Characterization of microstructural anisotropy in cancellous bone using a second rank tensor. J Mater Sci. 1985;19:761-767.

35. Hosseini HS, Horák M, Zysset PK, Jirásek M. An over-non-local implicit gradient-enhanced damage-plastic model for trabecular bone under large compressive strains. Int J Numer Meth Biomed Eng. 2015;31(11). https://doi.org/10.1002/cnm.2728

36. Ferrari S, Lippuner K, Lamy O, Meier C. 2020 Recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO). Swiss Med Wkly. 2020;150:w20352.

37. Halper-Stromberg E, Gallo T, et al. Bone mineral density across the lifespan in patients with type 1 diabetes. J Clin Endocrinol Metab. 2020;105(3):746-753.

38. Hough FS, Pierroz DD, Cooper C, Ferrari SL. MECHANISMS IN ENDOCRINOLOGY: Mechanisms and evaluation of bone fragility in type 1 diabetes mellitus. Eur J Endocrinol. 2016;174(4):R127-R138.

39. Starup-Linde J, Eriksen SA, Lykkeboe S, Handberg A, Vestergaard P. Biochemical markers of bone turnover in diabetes patients—a meta-analysis, and a methodological study on the effects of glucose on bone markers. Osteoporos Int. 2014;25(6):1697-1708.

40. Saito M, Fuji K, Mori Y, Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in men with type 1 diabetes: a cross-sectional study. Endocr Connect. 2021;10(8):955-964.

41. Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabetes. 1995;44(7):775-782.

42. Ams LAG, Akhter MP, Drincic A, Recker RR. TRabecular bone histomorphometry in humans with type 1 diabetes mellitus. Bone. 2012;50(1):91-96.

43. Wang H, Bä Y, Xing Q, Jian-Ling D. Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis. BMJ Open. 2019;9(1):e024067.

44. Vilaca T, Walsh J, Eastell R. Discordant pattern of peripheral fractures in diabetes: a meta-analysis on the risk of wrist and ankle fractures. Osteoporos Int. 2019;30(1):135-143.

45. Sundh D, Nilsson M, Zoulakis M, et al. High-impact mechanical loading increases bone material strength in postmenopausal women—a 3-month intervention study. J Bone Miner Res. 2018;33(7):1242-1251.

46. Hardy R, Cooper R, Shah I, Harridge S, Guralnik J, Kuh D. Is chair rise performance a useful measure of leg power? Aging Clin Exp Res. 2010;22(5-6):412-418.

47. Benavent-Caballer V, Sendin-Magdalena A, Lison JF, et al. Physical factors underlying the timed “up and go” test in older adults. Geriatr Nurs. 2016;37(2):122-127.

48. de Bakker CMJ, Tseng W-J, Li Y, Zhao H, Liu XS. Clinical evaluation of bone strength and fracture risk. Curr Osteoporos Rep. 2017;15(1):32-42.

49. Farlay D, Armas LAG, Ginseys E, Akhter MP, Recker RR, Boivin G. Nonezymatic glycation and degree of mineralization are higher in bone from fractured patients with type 1 diabetes mellitus. J Bone Miner Res. 2016;31(1):190-195.

50. Poundarik AA, Wu P-C, Evis Z, et al. A direct role of collagen glycation in bone fracture. J Mech Behav Biomed Mater. 2015;52:120-130.

51. Lekkala S, Hunt HB, Donnelly E. Effects of diabetes on bone material properties. Curr Osteoporos Rep. 2019;17(6):455-464.

52. Syversen U, Mosti MP, Mynarek IM, et al. Evidence of impaired bone quality in men with type 1 diabetes: a cross-sectional study. Endocr Connect. 2021;10(8):955-964.

53. Zebaze RMD, Ghasem-Zadeh A, Bohte A, et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet. 2020;375(9727):1729-1736.

54. Heilmeyer U, Patsch JM. Diabetes and bone. Semin Musculoskelet Radiol. 2016;20(3):300-304.

55. Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5(1):1-41.

56. Samelson EJ, Broe KE, Xu H, et al. Cortical and trabecular bone micro-architecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study. Lancet Diabetes Endocrinol. 2019;7(1):34-43.

57. Liu C, Lv H, Niu P, Tan J, Ma Y. Association between diabetic neuropathy and osteoporosis in patients: a systematic review and meta-analysis. Arch Osteoporos. 2020;15(1):125.

58. Shanhogue VV, Hansen S, Frost M, Brixen K, Hermann AP. Bone dis- charge of bone density and micro-architecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study. Lancet Diabetes Endocrinol. 2020;7(10):300-304.

59. Verroken C, Pieters W, Beddeleem L, et al. Cortical bone size deficit in adult patients with type 1 diabetes mellitus. J Clin Endocrinol Metab. 2017;102(8):2887-2895.

60. Devaraja J, Jacques R, Paggiosi M, Clark C, Dimitri P. Impact of type 1 diabetes on skeletal integrity and strength in adolescents as assessed by HRpQCT. JBMJR Plus. 2020;4(11):e10422.

61. Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabetes. 1995;44(7):775-782.

62. Heilmeyer U, Patsch JM. Diabetes and bone. Semin Musculoskelet Radiol. 2016;20(3):300-304.

63. Devaraja J, Jacques R, Paggiosi M, Clark C, Dimitri P. Impact of type 1 diabetes on skeletal integrity and strength in adolescents as assessed by HRpQCT. JBMJR Plus. 2020;4(11):e10422.

64. Bechtold S, Putzker S, Bonfig W, Fuchs O, Dirlenbach I, Schwarz HP. Bone size normalizes with age in children and adolescents with type 1 diabetes. Diabetes Care. 2007;30(8):2046-2050.

65. Shanhogue VV, Hansen S, Frost M, Brixen K, Hermann AP. Bone disease in diabetes: another manifestation of microvascular disease? Lancet Diabetes Endocrinol. 2017;5(10):827-838.

66. Shanhogue VV, Brixen K, Hansen S. Age- and sex-related changes in bone microarchitecture and estimated strength: a three-year prospective study using HRpQCT. J Bone Miner Res. 2016;31(8):1541-1549.

67. Ramchand SK, Seeman E. The influence of cortical porosity on the strength of bone during growth and advancing age. Curr Osteoporos Rep. 2018;16(5):561-572.